NCM
CATX icon

Nantahala Capital Management’s Perspective Therapeutics CATX Stock Holding History

Nantahala Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.93M Buy
+2,325,450
New +$8.79M 0.26% 90

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Nantahala Capital Management's CATX Position: Q2 2026 in Review

Nantahala Capital Management opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 2,325,450 shares worth $7.93M. The stake represents 0.26% of the portfolio and ranks #90 among its holdings.

132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Nantahala Capital Management held 2,325,450 shares of Perspective Therapeutics worth $7.93M as of Q2 2026.
  • Perspective Therapeutics was a new Nantahala Capital Management position in Q2 2026.
  • Perspective Therapeutics made up 0.26% of Nantahala Capital Management's portfolio in Q2 2026, its #90 holding.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.